Palvella Therapeutics, Inc.

Phase 3 Confirmed

QTORIN 3.9% rapamycin anhydrous gel

microcystic lymphatic malformations

Resolved

133days ago

Phase 3 readout · Feb 24, 2026

What's at stake Phase 3 trial results for QTORIN 3.9% rapamycin anhydrous gel in microcystic lymphatic malformations are due Feb 24, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 15h ago

“to present the topline results from the Company's Phase 3 SELVA study of QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations.”

Add to calendar Post on X Reddit

Provenance